WuXi Bio boosts share sale size to $599m

Allergen_Pills_Pharma_23May2017_Fotolia_230x150
By Jonathan Breen
01 Apr 2020

WuXi Biologics Holdings has pocketed HK$4.6bn ($599m) after selling part of its stake in subsidiary WuXi Biologics (Cayman).

The vendor, a Chinese biotechnology company, turned up on Tuesday with an aim to sell 41m secondary shares in WuXi Biologics, equal to 3.2% of the Hong Kong-listed subsidiary’s total share capital.

It offered the initial block with price guidance of HK$95.00 to HK$97.00 per share, eyeing proceeds ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial